0.84
-0.18%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Elutia
From its filings with the US Securities and Exchange Commission
Elutia is based in Silver Spring, Maryland and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ELUT. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $12.3m and net income of $53.4m. At that date it held total assets of $62.4m and shareholders' equity of $27.7m.
At Elutia, our mission is to humanize medicine so that patients can thrive without compromise. We develop proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Our focus is on addressing unmet medical needs and reducing complications associated with surgery, including infection, migration, erosion, implant rejection, and fibrosis. Our operations span research and development through the commercial distribution of biologic matrix products used in plastic and reconstructive surgery.
We have applied these capabilities to develop and commercialize products for specific surgical applications. As more fully described below, on October 1, 2025, we divested one such product family through the sale of substantially all of the assets related to our business of developing, commercializing, manufacturing, selling and marketing our cardiac implantable electronic device (“CIED”) products, EluPro™ and CanGaroo®, to Boston Scientific Corporation (“BSC”) and Cardiac Pacemakers Inc (“CPI”) for an aggregate purchase price of up to $88.0 million in cash. EluPro was the first antibiotic-eluting biologic matrix envelope for use with CIEDs. This transaction reflects the technical and commercial value of solutions developed using our biologic matrices and local drug delivery capabilities.
Quoted from its 10-K, filed 13 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Oct 2020
- Employees
- 26
- Website
- aziyo.com ↗
- Head office
- 12510 PROSPERITY DRIVE, SILVER SPRING, MD, 20904
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Kevin RakinLead Independent Chairman of the Board, since 2015$321,500
- Dr. C. Randal MillsPresident, Chief Executive Officer, Director, since 2015$4.5m
- Mr. Matthew FergusonChief Financial Officer$1.8m
- Dr. Michelle WilliamsChief Scientific Officer$1.6m
- Mr. David ColpmanIndependent Director$138,500
- Ms. Maybelle JordanIndependent Director$141,000
- Ms. Brigid MakesIndependent Director$161,000
- Mr. W. Matthew ZugaIndependent Director$121,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 1
- Governance
- 0
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aziyo Biologics Inc. possesses several key strengths that contribute to its success in the biologics industry. These strengths include:
Weaknesses
- Despite its overall success, Aziyo Biologics Inc. faces certain weaknesses that could hinder its growth and competitiveness. These weaknesses include:
Opportunities
- Aziyo Biologics Inc. has several opportunities for further growth and expansion. These opportunities include:
Threats
- Aziyo Biologics Inc. faces various threats that could potentially disrupt its operations and market position. These threats include:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.